Halozyme raises 2025 guidance: rev $1.15-1.225B, adj EBITDA $755-805M, $250M ASR

HALOZYME THERAPEUTICS, INC.

2024-FY EPS reported $3.43 revenue$1,015,324,000

Raises 2025 total revenue guidance to $1,150-$1,225M, representing 16-23% YoY growth from 2024 midpoint.
Raises 2025 adjusted EBITDA guidance to $755-$805M (24-32% YoY) and non-GAAP diluted EPS to $4.95-$5.35 (21-30% YoY).
Announces new $250M accelerated share repurchase (ASR) under existing $750M share repurchase program.
Reiterates 2024 preliminary unaudited guidance: revenue $970-$1,020M, adjusted EBITDA $595-$625M, non-GAAP EPS $4.00-$4.20.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.